NEXT SCIENCE LIMITED

Next Science Limited expects an increase in product sales for 2QFY23, reaching over US$5.6 million, compared to the sales of US$4.4 million in 1QFY23.
The company's sales for 1HFY23 are projected to significantly exceed the sales of 1HFY22 (US$5.2m) and 2HFY22 (US$6.1m), thanks to heightened investment in sales and marketing.
The Wound Care DME business saw a milestone with monthly sales surpassing $1 million in April 2023, evidencing maintained sales momentum in the commercial wound care market throughout the current quarter.

2023-06-29 09:44:00

Next Science Limited appoints Harry Thomas Hall, IV (I.V.) as its new Managing Director and Chief Executive Officer (CEO), starting on 10 July 2023.
I.V. has 28 years of experience in the global medical device industry, holding senior roles at DePuy Synthes, a subsidiary of Johnson & Johnson.
Current CEO, Judith Mitchell, will remain with the company until the end of July to ensure a smooth handover.

2023-06-16 08:25:00

ASX Briefs...everything...in 3 bullet points